p14ARF sensitizes human osteosarcoma cells to cisplatin-induced apoptosis in a p53-independent manner

Cancer Biology and Therapy

Volumn 6, Issue 7, 2007, Pages 1074-1080

  Yuan, Xiang Wei ^a   Zhu, Xiao Feng ^b   Huang, Xiu Fang ^a   Sheng, Pu Yi ^a   He, Ai Shan ^a   Yang, Zi Bo ^a   Deng, Rong ^b   Feng, Gong Kan ^b   Liao, Wei Ming ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Apoptosis; Cisplatin; Osteosarcoma; p14ARF; p53

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN BAX; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIZATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; UPREGULATION; WILD TYPE;

EID: 42449123680     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.7.4324     Document Type: Article

References (48)

1. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83:993-1000.
2. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-7.
3. 1-phase progression. Genes Dev 1999; 13:1501-12.
4. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D. A novel p16INK4A transcript. Cancer Res 1995; 55:2995-7.
5. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91:649-59.
6. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000; 10:94-9.
7. Markl ID, Jones PA. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res 1998; 58:5348-53.
8. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998; 12:2984-91.
9. Benassi MS, Molendini L, Gamberi G, Magagnoli G, Ragazzini P, Gobbi GA, Sangiorgi L, Pazzaglia L, Asp J, Brantsing C, Picci P. Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma. Cancer 2001; 92:3062-7.
10. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 1998; 12:2434-42.
11. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12:2424-33.
12. Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999; 13:2678-90.
13. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999; 13:2670-7.
14. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 2003; 1:1001-8.
15. Lohrum MA, Ashcroft M, Kubbutat MH, Vousden KH. Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr Biol 2000; 10:539-42.
16. Weber JD, Kuo ML, Bothner B, DiGiammarino EL, Kriwacki RW, Roussel MF, Sherr CJ. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol 2000; 20:2517-28.
17. Tao W, Levine AJ. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 1999; 96:6937-41.
18. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92:713-23.
19. Li Y, He L, Bruce A, Parihar K, Ingram A, Liu L, Tang D. p14ARF inhibits the growth of p53 deficient cells in a cell-specific manner. Biochim Biophys Acta 2006; 1763:787-96.
20. Tsuji K, Mizumoto K, Sudo H, Kouyama K, Ogata E, Matsuoka M. p53-independent apoptosis is induced by the p19ARF tumor suppressor. Biochem Biophys Res Commun 2002; 295:621-9.
21. Suzuki H, Kurita M, Mizumoto K, Nishimoto I, Ogata E, Matsuoka M. p19ARF-induced p53-independent apoptosis largely occurs through BAX. Biochem Biophys Res Commun 2003; 312:1273-7.
22. Young Jr JL, Miller RW. Incidence of malignant tumors in U. S. children. J Pediatr 1975; 86:254-8.
23. Bruland OS, Pihl A. On the current management of osteosarcoma: A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997; 33:1725-31.
24. Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD, Meyer WH. Metastatic osteosarcoma. Cancer 2006; 106:403-12.
25. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol 1997; 15:76-84.
26. Park YB, Park MJ, Kimura K, Shimizu K, Lee SH, Yokota J. Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet 2002; 133:105-11.
27. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59:657-63.
28. Ormerod MG. The study of apoptotic cells by flow cytometry. Leukemia 1998; 12:1013-25.
29. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55:4525-30.
30. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 2000; 120:91-8.
31. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. Alterations of the p15, p16,and p18 genes in osteosarcoma. Cancer Genet Cytogenet 1996; 86:136-42.
32. Oh JH, Kim HS, Kim HH, Kim WH, Lee SH. Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma. Clin Orthop Relat Res 2006; 442:216-22.
33. Zamble DB, Jacks T, Lippard SJ. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci USA 1998; 95:6163-8.
34. Serrano M. The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis 2000; 21:865-9.
35. Inoue R, Asker C, Klangby U, Pisa P, Wiman KG. Induction of the human ARF protein by serum starvation. Anticancer Res 1999; 19:2939-43.
36. Chen F, Li Y, Lu Z, Gao J, Chen J. Adenovirus-mediated Ink4a/ARF gene transfer significantly suppressed the growth of pancreatic carcinoma cells. Cancer Biol Ther 2005; 4:1348-54.
37. Nakazawa Y, Kamijo T, Koike K, Noda T. ARF tumor suppressor induces mitochondria-dependent apoptosis by modulation of mitochondrial Bcl-2 family proteins. J Biol Chem 2003; 278:27888-95.
38. Gallagher S, Kefford RF, Rizos H. Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis. Cell Cycle 2005; 4:465-72.
39. Peng L, Zhang W, Liu H, He D, Gao P. Effects of overexpressing p14ARF on the apoptosis in human melanoma cells irradiated with gamma-ray. Chinese Science Bulletin 2003; 48:1971-5.
40. Costantini P, Bruey JM, Castedo M, Metivier D, Loeffler M, Susin SA, Ravagnan L, Zamzami N, Garrido C, Kroemer G. Pre-processed caspase-9 contained in mitochondria participates in apoptosis. Cell Death Differ 2002; 9:82-8.
41. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. Embo J 1998; 17:5001-14.
42. Kim M, Sgagias M, Deng X, Jung YJ, Rikiyama T, Lee K, Ouellette M, Cowan K. Apoptosis induced by adenovirus-mediated p14ARF expression in U2OS osteosarcoma cells is associated with increased Fas expression. Biochem Biophys Res Commun 2004; 320:138-44.
43. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 2000; 14:2358-65.
44. Paliwal S, Pande S, Kovi RC, Sharpless NE, Bardeesy N, Grossman SR. Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol 2006; 26:2360-72.
45. Eymin B, Claverie P, Salon C, Leduc C, Col E, Brambilla E, Khochbin S, Gazzeri S. p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol Cell Biol 2006; 26:4339-50.
46. Guo-Chang F, Chu-Tse W. Transfer of p14ARF gene in drug-resistant human breast cancer MCF-7/Adr cells inhibits proliferation and reduces doxorubicin resistance. Cancer Lett 2000; 158:203-10.
47. Gao N, Hu YD, Cao XY, Zhou J, Cao SL. The exogenous wild-type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell lines. J Cancer Res Clin Oncol 2001; 127:359-67.
48. Al-Mohanna MA, Manogaran PS, Al-Mukhalafi Z, K AAH, Aboussekhra A. The tumor suppressor p16(INK4a) gene is a regulator of apoptosis induced by ultraviolet light and cisplatin. Oncogene 2004; 23:201-12.